China SXT Pharmaceuticals, Inc..
SXTC.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
China SXT Pharmaceuticals, Inc. is a China-based pharmaceutical company focusing on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine (TCM) products. The company specializes in granules, which are concentrated extracts from Chinese herbs that patients can m...Show More
Better Health for All
20
China SXT Pharmaceuticals, Inc. (SXTC) focuses entirely on Traditional Chinese Medicine (TCM) products, which are designed to provide health benefits.
1
Its products, such as Kuihuapan and Zhudanfen, are indicated for conditions like dizziness, tinnitus, joint pain, hyperuricemia, gout, hypertension, cough, asthma, fever, thirst, and red eyes.
2
Zhudanfen is also listed in the National Medical Insurance Catalogue (No. 697), indicating recognized medical utility.
3
There is no evidence of any products having negative health consequences, suggesting the company's entire portfolio is devoted to health improvement.
4
Fair Money & Economic Opportunity
0
China SXT Pharmaceuticals, Inc. is a pharmaceutical company focused on Traditional Chinese Medicine products, manufacturing, and distribution to hospitals and pharmacies.
1
Its core business activities do not involve lending, insuring, moving, or storing money for consumers.
2
The company's interest income was €0.00 Mil as of September 2024.
3
Therefore, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcome, financial literacy initiatives, debt burden ratio, geographic inclusion, and product simplicity, are not applicable. There is no evidence of profit reinvestment in community finance or profit-sharing with underserved communities.
4
Fair Pay & Worker Respect
0
No information was found in the provided article regarding living wage coverage, CEO to median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage for SXTC.US.
1
Fair Trade & Ethical Sourcing
0
The provided articles do not contain any specific, quantitative data or concrete evidence regarding the company's current performance on fair trade certifications, audit frequency, forced or child labor incidents, supply chain traceability coverage, remediation speed, ethical clause coverage in supplier contracts, share of high-risk materials, or supplier diversity spend.
1
While the company mentions plans and aims to improve supply chain transparency, traceability, and quality oversight, and to explore AI for these purposes,
2
these are forward-looking statements and not evidence of current actions or achieved outcomes.
Honest & Fair Business
0
No evidence available to assess China SXT Pharmaceuticals, Inc. on Honest & Fair Business.
Kind to Animals
0
No specific, concrete evidence regarding the company's animal welfare practices, policies, or performance was found in the provided articles. The articles explicitly stated an inability to access external websites, thus no content was available for assessment against the 'Kind to Animals' value KPIs.
1
No War, No Weapons
0
No evidence available to assess China SXT Pharmaceuticals, Inc. on No War, No Weapons.
Planet-Friendly Business
-30
In 2023, the company achieved a recycling rate of 67.3% for pharmaceutical production waste.
1
The company has zero major environmental compliance violations, with minor notices addressed swiftly. It operates under stringent Chinese environmental regulations, including 142 new environmental protection regulations in pharmaceutical manufacturing between 2022 and 2023, with mandatory emissions reduction targets of 15-25%.
2
The company also adheres to compliance requirements for waste water treatment (98.5% chemical oxygen demand reduction), air emission control (85% particulate matter reduction), and hazardous chemical disposal (99.7% safe disposal).
3
Respect for Cultures & Communities
0
No evidence available to assess China SXT Pharmaceuticals, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
No specific, concrete evidence was found in the provided articles to assess the company against any of the 'Safe & Smart Tech' KPIs. The articles primarily focus on financial performance, corporate structure, and general regulatory risks related to operating in China and being listed overseas, such as the Holding Foreign Companies Accountable Act (HFCAA) and PRC government oversight, including cybersecurity reviews.
1
However, they do not provide details on the company's specific practices or performance in data protection, cybersecurity investment, AI ethics, privacy certifications, security training, encryption implementation, AI audit practices, algorithmic transparency, unauthorized data use, user data control, authentication security, vulnerability management, bug bounty programs, privacy by design, security testing coverage, data minimization, compliance with privacy regulations, algorithmic harm remediation, or digital rights advocacy.
Zero Waste & Sustainable Products
-40
In 2023, the company achieved a 67.3% recycling rate for pharmaceutical waste.
1
It has implemented waste reduction initiatives, specifically optimizing raw materials and processes to minimize new pollutant generation at the source.
2
The company has established company-wide waste reduction targets with timelines, driven by the need to meet new industrial energy consumption and carbon intensity reduction standards mandated by the 14th Five-Year Plan and 2025 environmental targets.
3
For its supply chain, new policies effective March 1, 2026, require medicinal herb procurement to prioritize Good Agricultural Practices (GAP) standards and guide raw material suppliers to establish complete traceability systems, ensuring procurement from suppliers with robust quality management systems.
4
The company has had no waste disposal violations in the past three years.